Kessler Topaz Meltzer & Check, LLP: Investigation on Behalf of Sesen Bio, Inc. Shareholders

Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of purchasers of Sesen Bio, Inc. (NASDAQ: SESN) (“Sesen”) securities between February 17, 2021 and August 12, 2021.

Sesen investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.

Sesen is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. Sesen’s lead program is Vicineum™, also known as oportuzumab monatox. Vicineum is being developed for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). 

On August 13, 2021, Sesen announced that the U.S. Food and Drug Administration (“FDA”) declined to approve its Biologics License Application for its bladder cancer treatment Vicineum in its current form. The FDA provided certain “recommendations specific to additional clinical/statistical data and analyses in addition to Chemistry, Manufacturing and Controls (CMC) issues pertaining to a recent pre-approval inspection and product quality.” 

Following this news, Sesen’s stock price fell $2.80 per share, or 57%, to close at $2.11 per share on August 13, 2021.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  James Maro, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at [email protected].